Novo Nordisk today announced the launch of 34 briefs highlighting the breadth of its portfolio in the upcoming 84u American Diabetes Association (ADA) Scientific Sessions. The conference will be held in person and virtually from June 21-24, 2024 in Orlando, USA.
Additional data from three landmark semaglutide trials will also be presented in special scientific sessions. The trials are evaluating additional potential benefits of semaglutide, including assessment of renal and cardiovascular endpoints in people with type 2 diabetes and chronic kidney disease (FLOW, semaglutide 1.0 mg) and cardiovascular and glucose-related endpoints in subjects with obesity and cardiovascular disease, with and without diabetes (SELECT and STEP HFpEF, semaglutide 2.4 mg).
We recognize that cardiometabolic conditions such as cardiovascular disease, chronic kidney disease, obesity and type 2 diabetes are often linked and may occur in the same patient. We need to develop drugs that address multiple aspects of disease. The overall figures presented at this year’s ADA reflect this goal. Specifically, data from FLOW and SELECT examine ways to address common comorbidities of diabetes and obesity, such as kidney disease and cardiovascular disease.”
Stephen Gough, senior vice president and global chief medical officer, Novo Nordisk
All abstracts will be published on the journal’s website Diabetes®. Data from the scientific sessions will be available after their presentation.
Summary of presentations
Scientific sessions
The following data will be presented in the special scientific sessions as part of the scientific agenda of the conference:
| The First Exclusive Renal Outcome Trial With Once-Weekly GLP1-RA Semaglutide Trial Results – FLOW (Scientific Session, June 24, 1:30–3:00 PM EST) |
| SELECT Trial – New Tests for Glucose, Inflammation and Heart Failure (Scientific Session, June 22, 08:00–09:00 EST) |
| The STEP-HFpEF and STEP-HFpEF-DM Trials – Targeting Obesity to Treat Heart Failure (Scientific Session, June 23, 4:30–6:00 PM EST) |
Poster and oral presentations
The following abstracts were submitted by Novo Nordisk and are accepted for presentation at the conference:
| Diabetes |
| Uzbek® (semaglutide once weekly 1.0 mg) |
- Comparative effectiveness of semaglutide in T2D – year 2 results of a randomized pragmatic clinical trial (230-OR)
|
- Long-term efficacy associated with once-weekly semaglutide maintenance doses in US adults with poorly controlled T2D (766-P)
|
- Semaglutide in patients with peripheral artery disease and type 2 diabetes: comorbidities and concomitant medications from the STRIDE (784-P) trial
|
- Real-world impact of once-weekly injectable semaglutide on weight, BMI and HbA1c outcomes in type 2 diabetes: an observational study (PAUSE) (857-P)
|
- Actual impact of once-weekly injectable semaglutide (sema OW) versus sodium-glucose cotransporter 2 (SGLT2i) inhibitors on HbA1c, weight, and health care resource utilization (HCRU) outcomes in type 2 diabetes (Tservational Study) (PAUSE) (1884) -LB)
|
| Rybelsus® (once daily oral semaglutide) |
- Evaluation of the efficacy of oral semaglutide in baseline Chinese T2D patients: post hoc analysis of PIONEER 11 and 12 (752-P)
|
- The real-world impact of fasting on adherence to dosing guidelines and efficacy of oral semaglutide during Ramadan in subjects with type 2 diabetes: O-SEMA-Fast (808-P) subanalysis
|
| CagriSema |
- CagriSema improves insulin sensitivity in diet-induced obese rats (763-P)
|
| Once a week insulin icodec |
- Healthcare Resource Utilization and Costs with Early vs. Delayed Initiation of Basal Insulin (816-P)
|
- Demographic, clinical, and treatment characteristics of patients with early versus delayed initiation of basal insulin (817-P)
|
- No evidence of increased hypoglycaemia associated with physical activity with once-weekly icodec insulin versus once-daily basal insulin in T1D: META 6 (824-P)
|
- Efficacy and safety of once-weekly icodec insulin versus once-daily basal insulin in subjects with T2D due to renal function: META 1–5 (826-P)
|
- No evidence of increased hypoglycaemia associated with physical activity with once-weekly icodec insulin versus once-daily basal insulin in T2D: META 1-5 (830-P)
|
- Adherence to app-based dose guidance for once-weekly insulin icodec in insulin-free T2D: post hoc analysis of ONWARDS 5 (836-P)
|
- Effect of age on the efficacy and safety of once-weekly insulin icodec versus once-daily insulin in T2D (META 1–5) (838-P)
|
- Efficacy and safety of once-weekly icodec versus once-daily basal insulin in type 2 diabetes according to initial use of glucagon-like peptide-1 receptor agonists: META 1-5 (840-P)
|
- Efficacy and safety of once-weekly icodec insulin versus once-daily basal insulin in T2D by ethnicity and race: META 1–5 (841-P)
|
- The cost-effectiveness of icodec insulin for the treatment of type 2 diabetes in Canada (1046-P)
|
- Outcomes and safety outcomes of once-weekly insulin icodec versus once-daily insulin degludec in T1D according to glycemic variability: ONWARDS 6 post hoc analysis (1882-LB)
|
| Daily insulins |
- Effect of the functionally selective insulin analog NNC-965 on cardiac structure and function versus insulin glargine (IGla) (822-P)
|
- Improved glycemic control in people with type 2 diabetes (T2D) starting or switching to insulin degludec/insulin aspart (IDegAsp) in a real-world setting in China (publication only)
|
| General diabetes |
- Persistence and adherence of once-weekly GLP-1 receptor agonists in patients with type 2 diabetes and atherosclerotic cardiovascular disease in a real-world setting (740-P)
|
- Effect of newer GLP-1 RAs on HbA1c in US adults with type 2 diabetes: a population-level time-series analysis (774-P)
|
- Understanding attitudes about basal insulin: insights from a global survey of people with type 2 diabetes (833-P)
|
|
- Prevalence of atherosclerotic cardiovascular disease in adults with type 2 diabetes in Jordan: the PACT-MEA study (1789-LB)
|
- In vivo chain cleavage of human insulin (2032-LB)
|
| Digital Health |
- Time-to-range improvement after the launch of the smart insulin pen in Austria (842-P)
|
- Multinational Analysis of Factors Associated with Missed Insulin Bolus Injections Using Smart Pen Data (843-P)
|
| Portliness |
| Wegovy® (semaglutide once weekly 2.4 mg) |
- CONCRETE – characterization of patients receiving telemedicine and branded antiobesity drugs for medical weight management: a retrospective analysis (1684-P)
|
- Clinical outcomes in obese or overweight patients treated with semaglutide 2.4 mg: a real-world retrospective cohort study in the United States (SCOPE 2) (1691-P)
|
- Modeling the effect of semaglutide 2.4 mg in US patients with atherosclerotic cardiovascular disease and BMI ≥27 kg/m2 (1981-LB)
|
| General obesity |
- Patient-centered clinical decision support for weight management: a proof-of-concept study (1101-P)
|
- Prevalence, characteristics, and clinical burden among patients with overweight or obesity and established ASCVD in a real-world US setting (1692-P)
|
About Ozempic®
Once-weekly subcutaneous semaglutide is approved in doses of 0.5 mg, 1.0 mg, and 2.0 mg under the brand name Ozempic® and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes and to reduce the risk of serious adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with diabetes type 2 and cardiovascular disease was diagnosed.
About Rybelsus®
Oral semaglutide is administered once daily and is approved for use in three therapeutic doses, 3 mg, 7 mg, and 14 mg under the brand name Rybelsus®. Indicated for the treatment of adults with poorly controlled type 2 diabetes mellitus to improve glycemic control as an adjunct to diet and exercise.
About Wegovy®
Subcutaneous semaglutide 2.4 mg once weekly is approved under the brand name Wegovy® and is indicated in combination with a reduced-calorie diet and increased physical activity to reduce the risk of serious adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with established cardiovascular disease and obesity or overweight, as well as for reduction of excess body weight and long-term maintenance of weight reduction in adult and pediatric patients aged 12 years and older with obesity and in overweight adults in the presence of at least one weight-related comorbidity.
